Relay Therapeutics, Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.06M82.65M3.03M1.38M25.55M10.01M
Gross Profit -0.06M82.65M3.03M1.38M25.55M10.01M
Operating items
Research & Development 70.31M99.86M172.65M246.35M330.02M319.09M
Selling, General & Administrative 13.74M38.59M57.39M65.98M74.95M76.59M
Other Operating Expenses 137.69M-11.68M-6.42M-13.21M
Operating Expenses 84.05M138.45M367.73M300.66M398.55M382.48M
Operating Income -84.05M-55.80M-364.70M-299.27M-373.00M-372.47M
EBIT -84.05M-55.80M-364.70M-299.27M-373.00M-372.47M
Non-operating items
Interest & Investment Income 8.80M3.40M0.83M8.79M31.05M34.75M
Other Non Operating Income 8.74M3.38M0.83M8.77M31.03M34.76M
Non Operating Income 8.74M3.38M0.83M8.77M31.03M34.76M
Net income details
EBT -75.31M-52.41M-363.87M-290.49M-341.95M-337.72M
Profit After Tax -75.31M-52.41M-363.87M-290.51M-341.97M-337.71M
Income from Continuing Operations -75.31M-52.41M-363.87M-290.49M-341.95M-337.72M
Consolidated Net Income -75.31M-52.41M-363.87M-290.49M-341.95M-337.72M
Income towards Parent Company -75.31M-52.41M-363.87M-290.49M-341.95M-337.72M
Net Income towards Common Stockholders -75.31M-230.20M-363.87M-290.51M-341.95M-337.72M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 89.98M108.04M120.89M123.27M167.38M
EBITDA -74.98M-52.67M-365.02M-299.84M-331.75M-338.50M
Shares Outstanding 89.91M108.21M121.11M127.46M167.76M